A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Clinical Cancer Research2020Vol. 26(13), pp. 3193–3201
Citations Over TimeTop 10% of 2020 papers
Michael A. Postow, Susan J. Knox, Debra A. Goldman, Yuval Elhanati, Vikram Mavinkurve, Phillip Wong, Darragh Halpenny, Sunil K. Reddy, Kenya Vado, Danielle McCabe, Kristen Aufiero Ramirez, Mary Macri, Paul Schwarzenberger, Toni Ricciardi, Aileen Ryan, Ralph Venhaus, Parisa Momtaz, Alexander N. Shoushtari, Margaret K. Callahan, Paul B. Chapman, Jedd D. Wolchok, Priyanka B. Subrahmanyam, Holden T. Maecker, Katherine S. Panageas, Christopher A. Barker
Abstract
RT with nivolumab and ipilimumab was safe compared with historical data of nivolumab and ipilimumab alone. Immunologic effects were observed in the peripheral blood. Randomized studies are ongoing to assess whether RT increases the efficacy of nivolumab and ipilimumab.
Related Papers
- → Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,640 cited
- → Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab(2021)13 cited
- → Utility Values Across Lines of Therapy in Immuno-Oncology Treatments: An Example from Advanced Melanoma(2017)
- → Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients(2023)
- → TNFSF9 is associated with favor tumor immune microenvironment in patients with renal cell carcinoma who are treated with the combination therapy of nivolumab and ipilimumab(2024)